Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000230378 | SCV000284510 | likely benign | Neurofibromatosis, type 1 | 2025-02-02 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000570248 | SCV000662761 | likely benign | Hereditary cancer-predisposing syndrome | 2015-03-27 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Gene |
RCV001582762 | SCV001820607 | likely benign | not provided | 2018-11-21 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000230378 | SCV002561294 | likely benign | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001582762 | SCV005432099 | likely benign | not provided | 2024-09-01 | criteria provided, single submitter | clinical testing | NF1: BP4, BP7 |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV005238756 | SCV005884810 | likely benign | not specified | 2024-12-06 | criteria provided, single submitter | clinical testing |